Drugs / AT-III (Human)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02037555 | Jun 2014 → Jan 2018 | — | Grifols Therapeutics LLC | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AT-III (Human) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02037555 ↗ |
| Modality | Protein / enzyme biologic | “AT-III (Human) is an antithrombin concentrate prepared from pooled human plasma.” NCT02037555 ↗ |
| Route | Intravenous | “AT-III (Human) is provided as a freeze-dried preparation for intravenous use.” NCT02037555 ↗ |